Researchers at the University of Arizona Cancer Center recently unveiled data on a trial comparing "serological and cellular immune response after...BNT162b2 vaccination of patients with solid tumours on active cytotoxic chemotherapy compared to healthy controls..." The study background informs readers that antibody responses decline after a first dose of the mRNA vaccine for patients with solid or haematological tumours, but markedly improve after a second dose. 20 patients with gastrointestinal and breast cancer diagnoses from the original study cohort agreed to a third dose of the mRNA vaccine. "AT one week after a third immunization, 16 participants demonstrated a median threefold increase in neutralizing antibody responses."
To read more about this study, click here.
Study mentioned: Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature Medicine; Published online 30 September 2021. https://doi.org/10.1038/s41591-021-01542-z
No comments:
Post a Comment